PT2895188T - Etanercept dobrado corretamente de pureza elevada e rendimento excelente - Google Patents

Etanercept dobrado corretamente de pureza elevada e rendimento excelente

Info

Publication number
PT2895188T
PT2895188T PT138380167T PT13838016T PT2895188T PT 2895188 T PT2895188 T PT 2895188T PT 138380167 T PT138380167 T PT 138380167T PT 13838016 T PT13838016 T PT 13838016T PT 2895188 T PT2895188 T PT 2895188T
Authority
PT
Portugal
Prior art keywords
high purity
correctly folded
excellent yield
folded etanercept
etanercept
Prior art date
Application number
PT138380167T
Other languages
English (en)
Inventor
Arakawa Tsutomu
Farrar Douglas
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2895188(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of PT2895188T publication Critical patent/PT2895188T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
PT138380167T 2012-09-11 2013-09-10 Etanercept dobrado corretamente de pureza elevada e rendimento excelente PT2895188T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11

Publications (1)

Publication Number Publication Date
PT2895188T true PT2895188T (pt) 2018-02-08

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138380167T PT2895188T (pt) 2012-09-11 2013-09-10 Etanercept dobrado corretamente de pureza elevada e rendimento excelente

Country Status (32)

Country Link
US (6) US20140072560A1 (pt)
EP (1) EP2895188B1 (pt)
JP (3) JP2015533797A (pt)
KR (2) KR102250937B1 (pt)
CN (2) CN104902914B (pt)
AR (1) AR092532A1 (pt)
AU (2) AU2013315750B9 (pt)
BR (1) BR112015005161A2 (pt)
CA (1) CA2882551A1 (pt)
CL (1) CL2015000572A1 (pt)
CO (1) CO7400876A2 (pt)
CY (1) CY1120062T1 (pt)
DK (1) DK2895188T3 (pt)
DO (1) DOP2015000055A (pt)
EA (1) EA031324B1 (pt)
EC (1) ECSP15014138A (pt)
ES (1) ES2657377T3 (pt)
HR (1) HRP20180182T1 (pt)
HU (1) HUE036524T2 (pt)
IL (2) IL237311B (pt)
IN (1) IN2015KN00452A (pt)
LT (1) LT2895188T (pt)
MX (2) MX360044B (pt)
NO (1) NO2972131T3 (pt)
PE (2) PE20150996A1 (pt)
PL (1) PL2895188T3 (pt)
PT (1) PT2895188T (pt)
RS (1) RS57013B1 (pt)
SG (1) SG11201501460RA (pt)
SI (1) SI2895188T1 (pt)
TW (2) TWI716649B (pt)
WO (1) WO2014043103A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
JP6220789B2 (ja) 2011-10-18 2017-10-25 コヒラス・バイオサイエンシズ・インコーポレイテッド 糖およびポリオールの組合せによって安定化されたエタネルセプト製剤
CN104902914B (zh) * 2012-09-11 2019-01-01 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
CN106536565A (zh) * 2014-06-13 2017-03-22 鲁宾有限公司 一种用于纯化TNFR‑Fc融合蛋白的方法
ES2733298T3 (es) 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
IL253218B (en) 2014-12-31 2022-08-01 Lg Chemical Ltd A method for preparing a tnfr–fc fusion protein containing a targeted content of unpurified components
US20180079796A1 (en) 2015-03-13 2018-03-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
CA3005484A1 (en) * 2015-11-18 2017-05-26 Merck Patent Gmbh Opposite ph-salt gradients for improved protein separations
BR112018009881A2 (pt) * 2015-11-18 2018-11-13 Merck Patent Gmbh separação de proteína aperfeiçoada em cromatografia de troca iônica
CN109563124A (zh) * 2016-06-17 2019-04-02 豪夫迈·罗氏有限公司 多特异性抗体的纯化
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
MX2019011343A (es) * 2017-03-24 2019-11-18 Council Scient Ind Res Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
WO2022195505A1 (en) * 2021-03-16 2022-09-22 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
ATE309376T1 (de) 1990-06-28 2005-11-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000062790A2 (en) 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
BR0108193A (pt) 2000-02-10 2003-02-25 Wyeth Corp Processo para tratamento ou inibição de dano celular ou morte celular
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
CA2438094C (en) 2001-02-23 2011-10-11 Immunex Corporation Increased recovery of active proteins
JP4583762B2 (ja) 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
BRPI0407649A (pt) 2003-02-28 2006-02-21 Ares Trading Sa formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
CN100509847C (zh) 2003-08-01 2009-07-08 安美基公司 结晶肿瘤坏死因子受体2多肽
RS20060259A (en) 2003-10-14 2008-08-07 Intermune Inc., Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
CA2552639C (en) * 2004-02-27 2012-05-01 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
WO2005082377A1 (ja) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
US8206981B2 (en) 2004-03-05 2012-06-26 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
AR058567A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Formulaciones de proteinas estables
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EP2021030A2 (en) 2006-04-21 2009-02-11 Amgen, Inc. Buffering agents for biopharmaceutical formulations
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
KR20090127326A (ko) 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
CN103977404A (zh) 2007-06-14 2014-08-13 比奥根艾迪克Ma公司 抗体制剂
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
EP2260054B1 (en) * 2008-02-29 2015-06-03 Biogen Idec MA Inc. Purified immunoglobulin fusion proteins and methods of their purification
EP2288617B1 (en) * 2008-06-05 2014-03-26 Affibody AB Polypeptide
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
SG177577A1 (en) 2009-08-07 2012-03-29 Emd Millipore Corp Methods for purifying a target protein from one or more impurities in a sample
HUE048980T2 (hu) 2009-08-11 2020-08-28 Hoffmann La Roche Fehérjék elõállítása glutaminmentes sejttenyésztõ táptalajban
EP2490780A4 (en) * 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF MIXED MODE CHROMATOGRAPHY FOR CAPTURE AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
WO2011134920A1 (en) 2010-04-26 2011-11-03 Novartis Ag Improved cell culture medium
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
US20130209465A1 (en) 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
JP2013536683A (ja) 2010-08-31 2013-09-26 フリエスランド ブランズ ビー．ブイ． 真核細胞のための培養培地
KR20130142128A (ko) * 2010-10-11 2013-12-27 애브비 인코포레이티드 단백질의 정제 방법
JP5996631B2 (ja) 2011-04-20 2016-09-21 サンド・アクチエンゲゼルシヤフト ＴＮＦＲ：Ｆｃ融合タンパク質の安定した医薬液剤
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
KR102061355B1 (ko) 2011-07-01 2019-12-31 바이오젠 엠에이 인코포레이티드 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법
KR102108663B1 (ko) 2011-07-01 2020-05-07 암젠 인크 포유동물 세포 배양
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
JP6223338B2 (ja) 2011-08-17 2017-11-01 アレス トレーディング ソシエテ アノニム 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
JP6220789B2 (ja) * 2011-10-18 2017-10-25 コヒラス・バイオサイエンシズ・インコーポレイテッド 糖およびポリオールの組合せによって安定化されたエタネルセプト製剤
BR112015000203A2 (pt) * 2012-07-09 2017-06-27 Coherus Biosciences Inc formulações de etanercept que exibem redução marcada em partículas sub-visíveis
CN104902914B (zh) * 2012-09-11 2019-01-01 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
EP3175282B1 (en) * 2014-07-31 2021-06-09 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
IL267452A (en) 2019-08-29
JP6913066B2 (ja) 2021-08-04
US10954294B2 (en) 2021-03-23
CN104902914A (zh) 2015-09-09
PE20200607A1 (es) 2020-03-10
JP2019038817A (ja) 2019-03-14
EA201590542A1 (ru) 2015-07-30
TWI609877B (zh) 2018-01-01
US20140072560A1 (en) 2014-03-13
MX2015003090A (es) 2015-07-14
SI2895188T1 (en) 2018-05-31
CN110051823A (zh) 2019-07-26
US10947306B2 (en) 2021-03-16
DOP2015000055A (es) 2015-04-30
BR112015005161A2 (pt) 2017-07-04
US11001627B2 (en) 2021-05-11
TW201803593A (zh) 2018-02-01
MX360044B (es) 2018-10-19
IN2015KN00452A (pt) 2015-07-17
JP2015533797A (ja) 2015-11-26
PE20150996A1 (es) 2015-08-01
CN104902914B (zh) 2019-01-01
PL2895188T3 (pl) 2018-06-29
JP2021100929A (ja) 2021-07-08
TWI716649B (zh) 2021-01-21
KR102133699B1 (ko) 2020-07-14
IL237311A0 (en) 2015-04-30
US10954293B2 (en) 2021-03-23
AU2018247244A1 (en) 2018-11-01
EA031324B1 (ru) 2018-12-28
KR20150056601A (ko) 2015-05-26
TW201425331A (zh) 2014-07-01
HUE036524T2 (hu) 2018-07-30
AU2018247244B2 (en) 2020-05-28
ES2657377T3 (es) 2018-03-05
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (pt) 2018-04-21
HRP20180182T1 (hr) 2018-04-20
US20190300600A1 (en) 2019-10-03
US20190300602A1 (en) 2019-10-03
US20180037642A1 (en) 2018-02-08
CA2882551A1 (en) 2014-03-20
AU2013315750A1 (en) 2015-03-05
KR20200085937A (ko) 2020-07-15
CL2015000572A1 (es) 2016-02-05
RS57013B1 (sr) 2018-05-31
WO2014043103A1 (en) 2014-03-20
AR092532A1 (es) 2015-04-22
ECSP15014138A (es) 2016-01-29
DK2895188T3 (en) 2018-02-26
MX2018012749A (es) 2020-11-12
US20190300601A1 (en) 2019-10-03
LT2895188T (lt) 2018-04-10
EP2895188A1 (en) 2015-07-22
US10954295B2 (en) 2021-03-23
IL267452B (en) 2021-05-31
US20190330325A1 (en) 2019-10-31
IL237311B (en) 2019-07-31
EP2895188A4 (en) 2016-05-25
AU2013315750B2 (en) 2018-07-12
EP2895188B1 (en) 2017-11-15
AU2013315750B9 (en) 2018-11-15
CO7400876A2 (es) 2015-09-30
SG11201501460RA (en) 2015-04-29
CY1120062T1 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
IL267452B (en) Ethanercept is correctly folded with a high degree of cleanliness and excellent utilization
HK1206828A1 (en) Intelligent presentation of documents
GB2499314B (en) Replacement-gate finfet structure and process
ZA201500231B (en) Photovoltaic frame fastener
EP2903715A4 (en) TECHNOLOGY FOR ACOUSTOPHORETIC SEPARATION WITH MULTI-DIMENSIONAL STANDING WAVES
HK1211957A1 (en) Antibodies to risperidone haptens and use thereof
GB201201506D0 (en) Photovoltaic panel circuitry
EP2932375A4 (en) ADAPTATION OF OPPORTUNITY IN CONTEXT
EP2855745A4 (en) METHODS RELATING TO ADALIMUM AB
EP2806761A4 (en) COMPONENTS OF A SEASACK
GB2509046B (en) Improvement in or relating to capsules
PL2806773T3 (pl) Moduł do zaparzania
IL235425B (en) History of lysine-glutamic acid di-peptide
EP2774914A4 (en) N-BENZYLANILINE DERIVATIVE AND ITS USES
IL239824A0 (en) Use of inos inhibitors to increase viral survival in culture
EP2856514A4 (en) INTEGRATED PV MODULE CIRCUIT
HK1212733A1 (zh) 富含維生素發酵物的組合物和方法
GB201210817D0 (en) Balun
EP2864345A4 (en) NUCLEIC ACID PARTICLE CONJUGATES AND THERAPEUTIC APPLICATIONS THEREOF
GB2503225B (en) Balun
EP2892367A4 (en) CITRATE-RICH CALCIUM AND MAGNESIUM COMPOUND AND USES THEREOF
PT2906528T (pt) Processo para a obtenção de anilina pura
ZA201504198B (en) Methods for banana yield protection and enhancement
AU343221S (en) Zipper securing aid
AU343220S (en) Zipper securing aid